• PacBio Outlook 2018

    Omics! Omics! | Keith Robison gives his take on PacBio's recent presentation at the JP Morgan Healthcare Conference.

    Jan 18, 2018

  • Why Gene Therapy Is No Longer A Pipe Dream

    Pacific Standard | After decades of disappointment, cures to once-incurable diseases seem within reach.

    Jan 18, 2018

  • Celgene In Talks To Buy Juno Therapeutics

    New York Business Journal | Celgene is looking to purchase Juno Therapeutics, just one week after it announced that it was taking over Impact Biomedicines in a $7 billion transaction.

    Jan 17, 2018

  • Has Bio-IT Soured On Cloud?

    Bio-IT World | Bio-IT has swung the gamut of opinions on cloud solutions. First wary, then warming, now, perhaps, pulling back. The inconsistency comes as use cases evolve and costs are closely watched. But there’s no denying that the cloud lets researchers do things they’ve never done before. The trick is finding the right balance.

    Jan 17, 2018

  • Howard Jacob Leaving HudsonAlpha For AbbVie

    Bio-IT World | Less than three years after leaving the Medical College of Wisconsin for the HudsonAlpha Institute in Huntsville, Alabama, Howard Jacob is starting today as the Vice President of the Genomic Research Center at AbbVie.

    Jan 16, 2018

  • DNA Sequencing Holds Some Promise For Treating Tumors

    NPR | Sequencing the DNA of cancer tumors to help pinpoint treatment is an emerging element of precision medicine. While patients and doctors alike want these tests, they often don't benefit patients.

    Jan 15, 2018

  • 23andMe CEO Goes Beyond “Wall Of A White Coat”

    Bio-IT World | Speaking at the 36th annual JP Morgan Healthcare Conference, 23andMe’s CEO and co-founder Anne Wojcicki reflected on the scope of the 23andMe’s dataset, especially as it pertains to healthcare and drug discovery.

    Jan 15, 2018

  • JP Morgan 2018 News Roundup

    Bio-IT World | The 36th annual JP Morgan Healthcare Conference was held this week in San Francisco, bringing together more than 400 companies to showcase their growth and innovation. Here are some of the highlights and announcements we’ve collected from the conference.

    Jan 12, 2018

  • Nonprofit Price For New Childhood Blindness Therapy 4X Too High

    STAT | Luxturna, a gene therapy with a list price $850,000, is the latest flashpoint in the debate over how to afford innovative medicines.

    Jan 12, 2018